Dataset Information
Developments in Intralesional Therapy for Metastatic Melanoma.
Ontology highlight
ABSTRACT: Background
Locoregional advanced melanoma poses a complex clinical challenge that requires a multidisciplinary, patient-centered approach. Numerous agents have been studied for their suitability as intralesional therapy in the past decades, but few have successfully completed phase 3 clinical trial testing.Methods
The relevant medical literature was searched for articles regarding use of intralesional therapies in metastatic melanoma. Therapies with data from phase 2 or higher studies were selected for review. This review also summarizes the mechanisms of action, adverse-event profiles, and clinical data for these agents.Results
Intralesional therapies demonstrate promising effects in select patients with advanced melanoma. The optimal approach should be individually tailored and consist of a combination of intralesional therapies, regional perfusions, systemic immunotherapies, targeted therapies, and surgery, if necessary.Conclusions
Due to its relatively good local response rates and tolerable adverse-event profile, intralesional therapy may be a treatment option for select patients with unresectable, locally advanced or metastatic melanoma.
SUBMITTER: Sloot S
PROVIDER: S-EPMC4904721 | biostudies-literature | 2016 Jan
REPOSITORIES: biostudies-literature
Publications
Developments in Intralesional Therapy for Metastatic Melanoma.
Cancer control : journal of the Moffitt Cancer Center 20160101 1
<h4>Background</h4>Locoregional advanced melanoma poses a complex clinical challenge that requires a multidisciplinary, patient-centered approach. Numerous agents have been studied for their suitability as intralesional therapy in the past decades, but few have successfully completed phase 3 clinical trial testing.<h4>Methods</h4>The relevant medical literature was searched for articles regarding use of intralesional therapies in metastatic melanoma. Therapies with data from phase 2 or higher st ...[more]